Botox News and Research

RSS

Botox is a drug made from a toxin produced by the bacterium Clostridium botulinum. It's the same toxin that causes a life-threatening type of food poisoning called botulism. Doctors use it in small doses to treat health problems, including, temporary removal of facial wrinkles, severe underarm sweating, cervical dystonia - a neurological disorder that causes severe neck and shoulder muscle contractions, blepharospasm - uncontrollable blinking, strabismus - misaligned eyes. Botox injections work by weakening or paralyzing certain muscles or by blocking certain nerves. The effects last about three to four months. Side effects can include pain at the injection site, flu-like symptoms, headache and upset stomach. Injections in the face may also cause temporary drooping eyelids. You should not use Botox if you are pregnant or breast feeding.

Botox receives FDA approval for treatment of chronic migraine

The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.

18 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that two first-in-class agents — Merck's telcagepant and CoLucid's lasmiditan — will earn combined sales of approximately $1.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

11 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

USPTO approves Microdroplet botulinum toxin treatment

The patent application for Microdroplet botulinum toxin, a treatment that improves facial features without detracting from facial expressiveness, has been allowed to inventor Dr. Kenneth D. Steinsapir, M.D. on September 2, 2010.

5 Oct 2010

Warning on Australian clinics offering safe alternatives to mammograms

Experts have warned that some private clinics that are offering safe alternatives to mammograms as breast cancer screening are doing more harm than good. It is seen that clinics offering services like botox, liposuction and spray tans are increasingly providing breast cancer screening that uses thermal imaging and “electrical impedance” technology. These methods are being used on women as young as 20, with claims they can detect cancer years earlier than mammograms.

20 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

Botox maker agrees to pay $600 million for misbranding

The Associated Press: "Allergan Inc., the maker of wrinkle-smoothing Botox, has agreed to pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug. The Justice Department and the company said Wednesday in a statement it will plead guilty to one misdemeanor charge of 'misbranding,' in which the company's marketing led physicians to use Botox for unapproved uses. Those included the treatment of headache, pain, spasticity and cerebral palsy in children.

3 Sep 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

First Edition: September 2, 2010

Today's headlines include reports about a new study examining the impact of the health overhaul on the small business workforce.

2 Sep 2010

Scientist develops new ETS procedure to treat hyperhidrosis

Millions of people in the United States suffer from a medical condition that can unpredictably cause them to begin sweating as if they had just finished running a marathon.Hyperhidrosis, or excessive sweating, is a common disorder that first becomes noticeable during childhood or adolescence. People with hyperhidrosis could be doing something as leisurely as lying down or watching television and sweat will still soak their bodies.

2 Sep 2010

Event Pulse report reveals impact of new therapies on MS drug market

The study titled Event Pulse Preview: Multiple Sclerosis shows that 84% of neurologists expect to prescribe Gilenia for some MS patients if approved, but prescribing will likely be limited to second- or third-line therapy until concerns about safety and monitoring requirements are resolved.

1 Sep 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

ISAPS Biennial Global Survey of plastic surgeons and procedures

The International Society of Aesthetic Plastic Surgery is a world leader in plastic surgery. After a year-long process, the Society has produced the "ISAPS Biennial Global Surve" of plastic surgeons and procedures in the top 25 countries and regions – representing 75% of all procedures in 2009.The ISAPS Survey marks the first time reliable international plastic surgery data has been obtained and analyzed by independent statistical specialists.

9 Aug 2010

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

New study links facial expressions with written language

Your facial expression may tell the world what you are thinking or feeling. But it also affects your ability to understand written language related to emotions, according to research published in the July issue of Psychological Science, a journal of the Association for Psychological Science.

20 Jul 2010

Collagen Induction Therapy and Ultrasonic Microdermabrasion demonstrations at Lecada's open house

An open house on Thursday, June 17th, celebrated Lecada Medical Artistry's grand opening at 3710 West Azeele Street, Tampa. Lecada offers innovative treatments for face and body that provide aesthetic and anti-aging solutions designed to help you look and feel your best.

14 Jul 2010

MDT releases statement questioning AGD's priorities

The dentists who form Millennium Dental Technologies, Inc., and are pioneers of the patented LANAP protocol for the treatment of gum disease and the manufacturer of the PerioLase MVP-7 digital dental laser, today released a statement questioning the Academy of General Dentistry's priorities.

12 Jul 2010

Allergan receives UK MHRA authorisation of BOTOX for prophylaxis of headache in chronic migraine

Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). This is the first licence worldwide of BOTOX® for this indication, and is also the first prophylactic (preventative) treatment to receive a specific licence for patients with chronic migraine.

9 Jul 2010